This is an excellent summary of progress during the past year in all aspects of lung cancer, from prevention/detection through molecular therapies and future perspectives. Each section is written by a handful of international experts.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Multimodality Therapy
August 28, 2016
The authors tested the hypothesis that induction therapy improves survival in patients undergoing resection for clinical N1 disease using information from the National Cancer Data Base. 10% of over 5,000 pts were treated with induction therapy. They were 2:1 propensity matched with patients undergoing the traditional surgery first strategy. Among
July 15, 2016
This is a retrospective National Cancer Data Base cohort study of patients with pathologic stage T3 invasive NSCLC with separate tumor nodules in the same lobe. The goal was to determine with adjuvant chemotherapy increased survival.
Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter?
November 16, 2015
The relationship to institution type and survival after multimodality therapy for IIIA NSCLC was investigated using the NCDB (National Cancer Database). Academic medical centers had a higher incidence of induction therapy, lower postoperative mortality, and improved overall survival.
September 12, 2015
This randomized trial compared induction therapy for pathologically-proven N2/IIIA NSCLC with 3 cycles of cisplatinum and docetaxel chemotherapy alone to chemotherapy combined with 44 Gy of radiation therapy. 232 pts in 23 centers were enrolled over a 12 year period. No differences were identified in the chemotherapy vs chemoradiotherapy groups for
July 14, 2015
This meta-analysis evaluated results from 6 studies totalling 868 patients randomized to local control (radiotherapy vs surgery) after induction therapy for NSCLC with N2 disease. Four studies evaluated induction chemotherapy, the other 2 evaluated induction chemoradiotherapy. Differences in outcomes were not significant, but there was a strong tre
June 14, 2015
Trials evaluating the use of surgery in stage IIIB NSCLC are lacking. This study goes some way to address that and demonstrates that surgery as part of multi-modality therapy may result in a survival benefit.
June 12, 2015
This meta-analysis of published studies evaluated outcomes of multimodality therapy including resection for superior sulcus NSCLC invading the spine. 134 articles were evaluated, which included 135 patients. 63% had induction therapy, and all underwent en bloc resection. 52% had adjuvant therapy. Survival at 3,5, and 10 years was 57%, 42%, and 27
February 21, 2015
Indications for postoperative radiation therapy (PORT) for resected lung cancer are unclear. This study evaluated outcomes from the National Cancer Data Base 2004-2006, including 2115 patients resected with pathologic N2 NSCLC, of whom 918 (43%) received PORT. PORT was associated with better median survival (42 vs 38 mos, p=0.048) and was associat
February 16, 2015
Usually patients with prior cancer are excluded in lung cancer trials, but the impact on survival in lung cancer is not known. In a cohort of 102929 patients older than 65 with stage IV lung cancer, a propensity score analysis were performed and found that patients with prior cancer had better survival (all-cause and lung cancer-specific).